About this episode

The episode discusses key developments in myeloid neoplasms, focusing on AML and MDS, with insights from ASH 2025.

People in this episode

Host: Dr. Andreas Hausmann

Guest: Prof. Dr. med. Thomas Schroeder

Topics covered

• myeloid neoplasms
• acute myeloid leukemia
• allogeneic stem cell transplantation
• FLT3 inhibition
• combination therapies
• clinical outcomes

Keywords

• AML
• MDS
• Gilteritinib
• Sorafenib
• HMA
• Venetoclax
• stem cell transplantation
• clinical trials

Mentioned in this episode

Organizations: Universitätsklinikum in Essen

Products: Gilteritinib, Sorafenib, HMA, Venetoclax

Books & works: VERONA-Studie

More episodes of Hämatologie Shortcasts

• AML – Revolution oder Evolution? · February 27, 2026 · 26 min
• ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
• ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
• ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
• ASH 2025 – Neuigkeiten zur CLL · December 16, 2025 · 24 min
• ASH 2025 – Latebreaker · December 4, 2025 · 34 min

Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.